Figure | Paixin Creative
Recently, medical device companies have密集ly disclosed management changes.Foreign Enterprises
Recently,Global ECMO giant LivaNova announced the appointment of Vladimir A. Makatsaria as the company's Chief Executive Officer (CEO) and member of the Board of Directors, effective March 1, 2024.Makatsaria spent nearly 30 years of his career at Johnson & Johnson,Previously served as the Chairman of Johnson & Johnson's Ethicon group, and has also held positions such as Chairman of Johnson & Johnson China and Chairman of Johnson & Johnson's Asia-Pacific Medical Devices group.Makatsaria will replace Kozy, who has served as the interim CEO since April 2023. Kozy will continue to serve as the Chairman of the Board of LivaNova.LivaNova Board Chairman Bill Kozy said, "Vlad is a respected leader in the medical device industry, renowned for delivering results, driving innovation, and building great teams. The Board and I are highly confident that he is the right CEO to advance the company’s strategic plans and achieve our long-term growth objectives."February 5,Globus Medical announced the promotion of Keith Pfeil to Chief Operating Officer (COO) and Chief Financial Officer (CFO).Since August 2019, Pfeil has served as the company's Chief Financial Officer. He will further drive the company’s development along its strategic path through business and operational planning as well as financial performance management. He will oversee all daily operational activities and, in addition, supervise all financial activities.Last September, Globus Medical and NuVasive announced the completion of their merger.Both parties are among the top ten orthopedic companies globally. According to estimates, the merged company will become the world's second-largest spinal technology company, only after Medtronic."Globus Medical President and CEO Dan Scavilla said, 'I believe Pfeil will help us continue to improve operational efficiency, achieve the next phase of profitable growth, and ensure a successful ongoing integration following our merger with NuVasive, which continues to proceed as planned.'"On February 5, Inspire Medical Systems announced,Chairman Marilyn Carlson Nelson Retires; CEO Timothy P. Herbert to Assume Role as Chairman Effective at the Close of the Company’s Annual General Meeting on May 2Mr. Herbert is the founder of Inspire and has served as President and Chief Executive Officer since May 2007.It is reported that,The Board has appointed Gary Ellis as the Lead Independent Director. Mr. Ellis previously served as the Chief Financial Officer of Medtronic., appointed as a member of the Inspire Board of Directors in 2019.January 26,Boston Scientific Board Appoints Jonathan Monson as Senior Vice President of Investor Relations, Effective March 1, 2024.Mr. Monson currently serves as Senior Vice President, Global Financial Controller, and Chief Accounting Officer, a position he has held since July 2019; effective March 1, 2024, Mr. Monson will no longer serve as the company's Chief Accounting Officer.
On the same day,The Board appointed Emily Woodworth (Collins) as Senior Vice President, Global Controller and Chief Accounting Officer, effective March 1, 2024.Ms. Woodworth currently serves as the Vice President of Finance and Financial Director of the company's urology business, a position she has held since July 2019. Ms. Woodworth is expected to receive a base salary, participate in the company’s annual bonus plan and incentive stock award plan, and continue to be eligible for other employee benefit plans applicable to the company’s executives.
Domestic Enterprises
February 8,Jiangsu Yuyue Medical Equipment&Supply Co.,Ltd. Announces the Appointment of Mr. Zheng Hongzhe as Vice General Manager, Responsible for Corporate Strategy Development, Investment, and External Business Expansion.The term shall commence from the date of approval by the Second Special Meeting of the Sixth Board of Directors and end upon the expiration of the term of the Sixth Board of Directors.In addition,Due to internal work adjustments within the company, Mr. Zhang Yuyang will no longer serve as the company's securities affairs representative. After leaving this position, he will continue to hold other roles within the company, and the responsibilities of his previous role have been successfully handed over.The company has appointed Ms. Yang Xinyue as the company's securities affairs representative.Assist the Board Secretary in carrying out work, with the term commencing from the date of approval at the Second Special Meeting of the Sixth Board of Directors and ending upon the expiration of the Sixth Board of Directors.On February 8, Orient Gene announced that, in light of the company's actual operational and development needs, and following the nomination by the company's General Manager as well as the qualification review approval by the company’s Board of Directors Nomination Committee,The company's board of directors agreed to appoint Ms. Zheng Yuzi and Mr. Ouyang Yun as the company's deputy general managers., the term shall commence from the date of approval by this Board of Directors and end on the expiration date of the third Board of Directors.On February 7, EasyDiagnosis announced,Mr. Zhou Guohui applied to resign from the position of the company's financial director due to personal reasons.After resignation, Mr. Guohui Zhou will no longer hold any position in the company or its subsidiaries. The original term of Mr. Guohui Zhou was set to expire on October 21, 2025.Nominated by the Chairman of the Board,The company's board of directors agreed to appoint Mr. Wang Rui as the company's financial director., whose term will start from the date of approval by this board meeting until the expiration of the fourth board. The above proposal has been approved by the company's nomination committee and audit committee.
On February 6, Hotgen Biotech announced that, due to the company's operational and management needs and in line with its strategic planning, and upon the nomination of the company’s General Manager and review by the Nomination Committee,The company's board of directors agreed to appoint Li Yanzhao, Liu Xiaoli, and Jie Xiaochi as vice presidents of the company.Resumes of 3 senior executives are as follows:
On February 5, Hualan Corporation announced,Mr. Baoan Jiao intends to resign from the position of Head of the Company's Audit Department due to personal reasons, effective February 7, 2024. After his resignation, he will no longer hold any position within the company., the resignation report shall take effect from the date it is delivered to the company's board of directors. ▍Zhejiang Gongdong Medical Technology Co., Ltd.On February 3, Gongdong Medical announced that the board of directors of Zhejiang Gongdong Medical Technology Co., Ltd. (hereinafter referred to as "the Company") recently received a written resignation report from Mr. Pan Lei, the Company's financial director, due to personal reasons.Mr. Pan Lei has applied to resign from his position as the company's financial director. After stepping down as financial director, he will continue to serve in other roles within the company.As of the date of this announcement, Mr. Pan Lei does not directly hold any shares of the company, but indirectly holds 0.224% of the company's shares through Taizhou Jinchao Investment Management Partnership (Limited Partnership).To ensure the normal operation of the company's financial work,Before the appointment of a new Chief Financial Officer, Mr. Zhong Weifeng, a director and general manager of the company, will temporarily assume the responsibilities of the Chief Financial Officer. The company will complete the selection and appointment of the Chief Financial Officer as soon as possible in accordance with relevant regulations.On January 31, Tofflon announced that the board of directors of Tofflon Science and Technology Group Co., Ltd. (hereinafter referred to as "the Company") recently received the resignation report from Mr. Fang Qibin, the head of the Company's Audit Department.Mr. Fang Qibin resigned from his position as the head of the company's audit department due to personal reasons and will no longer hold any position in the company after resignation.Nominated by the Audit Committee of the Sixth Board of Directors of the company, the seventh (interim) meeting of the Sixth Board of Directors was held on January 31, 2024, during which the proposal "Regarding the Appointment of the Head of the Company's Audit Department" was reviewed and approved.The company's board of directors agreed to appoint Ms. Zhang Peipei as the head of the company's audit department., the term shall commence from the date of approval by this Board of Directors and end on the expiration date of the Sixth Board of Directors.WeChat ID: nrzx0321
